申联生物
(688098)
| 流通市值：23.41亿 | | | 总市值：23.41亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 78,741,129.63 | 303,414,652.03 | 248,302,819.25 | 126,375,941.3 |
| 营业收入 | 78,741,129.63 | 303,414,652.03 | 248,302,819.25 | 126,375,941.3 |
| 二、营业总成本 | 80,804,394.1 | 329,503,695.54 | 259,262,501.74 | 162,802,956.75 |
| 营业成本 | 32,384,277.78 | 120,611,552.52 | 96,550,396.54 | 52,574,910.4 |
| 税金及附加 | 1,135,772.06 | 4,364,696.61 | 3,321,252.96 | 2,069,219.01 |
| 销售费用 | 22,085,481.84 | 100,672,153.29 | 77,225,498.63 | 53,355,521.59 |
| 管理费用 | 14,136,293.86 | 55,234,455.58 | 44,995,343.8 | 29,561,924.64 |
| 研发费用 | 11,111,043.54 | 49,355,062.69 | 37,754,809.62 | 25,619,335.99 |
| 财务费用 | -48,474.98 | -734,225.15 | -584,799.81 | -377,954.88 |
| 其中:利息费用 | 68,249.99 | 17,062.5 | - | - |
| 其中:利息收入 | 131,664.05 | 810,938.91 | 616,342.74 | 396,195.42 |
| 加:公允价值变动收益 | 939,856.26 | 883,276.87 | -35,982.52 | 116,132.31 |
| 加:投资收益 | 395,061.42 | 1,785,944.86 | 1,418,148.9 | 1,006,922.34 |
| 资产处置收益 | - | 35,769.23 | - | - |
| 资产减值损失(新) | -13,753.64 | -28,177,425.29 | -18,409.77 | -26,623.65 |
| 信用减值损失(新) | -4,234,970.81 | -8,471,632.6 | -12,215,863.03 | -3,729,953.73 |
| 其他收益 | 850,483.61 | 3,522,429.88 | 2,848,837.55 | 2,180,605.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -4,126,587.63 | -56,510,680.56 | -18,962,951.36 | -36,879,933.02 |
| 加:营业外收入 | 0 | 23,304.32 | 66,882.31 | 14,113.06 |
| 减:营业外支出 | 3,221.41 | 306,945.28 | 309,101.48 | 284,972.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -4,129,809.04 | -56,794,321.52 | -19,205,170.53 | -37,150,792.27 |
| 减:所得税费用 | -75,203.57 | -8,045,757.13 | -2,184,727.05 | -715,176.24 |
| 六、净利润 | -4,054,605.47 | -48,748,564.39 | -17,020,443.48 | -36,435,616.03 |
| 持续经营净利润 | -4,054,605.47 | -48,748,564.39 | -17,020,443.48 | -36,435,616.03 |
| 归属于母公司股东的净利润 | -3,019,866.61 | -44,740,058.21 | -14,124,681.4 | -34,507,973.32 |
| 少数股东损益 | -1,034,738.86 | -4,008,506.18 | -2,895,762.08 | -1,927,642.71 |
| (一)基本每股收益 | -0.01 | -0.11 | -0.03 | -0.08 |
| (二)稀释每股收益 | -0.01 | -0.11 | -0.03 | -0.08 |
| 九、综合收益总额 | -4,054,605.47 | -48,748,564.39 | -17,020,443.48 | -36,435,616.03 |
| 归属于母公司股东的综合收益总额 | -3,019,866.61 | -44,740,058.21 | -14,124,681.4 | -34,507,973.32 |
| 归属于少数股东的综合收益总额 | -1,034,738.86 | -4,008,506.18 | -2,895,762.08 | -1,927,642.71 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |